R
Relay Therapeutics
A new breed of company at the intersection of computation and biotechnology that is committed to creating medicines that will have a transformative impact on patients
About Relay Therapeutics
Relay Therapeutics is a pioneering biotech company focused on revolutionizing drug discovery by placing protein motion at the core of its research. The company operates primarily in the pharmaceutical and biotechnology markets, targeting complex diseases that have been challenging to treat with existing methods. Relay Therapeutics serves a diverse range of clients, including patients, healthcare providers, and pharmaceutical companies.
Read full description
The company's business model revolves around its innovative Dynamo™ platform, which combines cutting-edge experimental and computational techniques to identify and develop new therapeutic candidates. This platform allows Relay to target proteins that have been difficult or impossible to drug in the past, thereby expanding the possibilities for effective treatments. Relay Therapeutics is particularly focused on precision oncology (cancer treatment tailored to individual genetic profiles) and genetic diseases.
Relay makes money through a combination of licensing agreements, collaborations, and the development of its own drug pipeline. For instance, the company has entered into a worldwide license and collaboration agreement with Genentech, a major player in the biotech industry. These partnerships not only provide immediate revenue but also validate the potential of Relay's technology and approach.
The company's ultimate goal is to bring life-changing medicines to patients, and it is actively involved in clinical trials to test the efficacy and safety of its drug candidates. Relay's team is described as highly integrated, collaborative, and entrepreneurial, which is essential for driving innovation in such a complex and competitive field.
At a glance
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Relay Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Third Rock Ventures
Nat Turner
BVF Partners
Section 32
Casdin Capital
EcoR1 Capital
Series B and later7 investors entered at this stage
SoftBank Vision Fund
SoftBank
Alexandria Venture Investments
Foresight Group
Tavistock Group
Perceptive Advisors
IEQ Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
33 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Relay Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Relay Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.